اخبار و اعلانات

 آمار

تعداد نشریات284
تعداد نشریات سازمان82
تعداد شماره‌ها3,067
تعداد مقالات34,232
تعداد مشاهده مقاله47,008,393
تعداد دریافت فایل اصل مقاله77,944,543
Hossain, M. J, Rahman, S. M. A, Emran, T. B, Mitra, S, Islam, M. R, Dhama, K. (1400). Recommendation and Roadmap of Mass Vaccination against Coronavirus Disease 2019 Pandemic in Bangladesh as a Lower-Middle-Income Country. سامانه مدیریت نشریات علمی, 76(6), 1823-1830. doi: 10.22092/ari.2021.356357.1824
M. J Hossain; S. M. A Rahman; T. B Emran; S Mitra; M. R Islam; K Dhama. "Recommendation and Roadmap of Mass Vaccination against Coronavirus Disease 2019 Pandemic in Bangladesh as a Lower-Middle-Income Country". سامانه مدیریت نشریات علمی, 76, 6, 1400, 1823-1830. doi: 10.22092/ari.2021.356357.1824
Hossain, M. J, Rahman, S. M. A, Emran, T. B, Mitra, S, Islam, M. R, Dhama, K. (1400). 'Recommendation and Roadmap of Mass Vaccination against Coronavirus Disease 2019 Pandemic in Bangladesh as a Lower-Middle-Income Country', سامانه مدیریت نشریات علمی, 76(6), pp. 1823-1830. doi: 10.22092/ari.2021.356357.1824
Hossain, M. J, Rahman, S. M. A, Emran, T. B, Mitra, S, Islam, M. R, Dhama, K. Recommendation and Roadmap of Mass Vaccination against Coronavirus Disease 2019 Pandemic in Bangladesh as a Lower-Middle-Income Country. سامانه مدیریت نشریات علمی, 1400; 76(6): 1823-1830. doi: 10.22092/ari.2021.356357.1824

Recommendation and Roadmap of Mass Vaccination against Coronavirus Disease 2019 Pandemic in Bangladesh as a Lower-Middle-Income Country

Archives of Razi Institute
مقاله 28، دوره 76، شماره 6، بهمن و اسفند 2021، صفحه 1823-1830    اصل مقاله (538.74 K)
نوع مقاله: Scientific Report
شناسه دیجیتال (DOI): 10.22092/ari.2021.356357.1824
نویسندگان
M. J Hossain* 1؛ S. M. A Rahman2؛ T. B Emran3؛ S Mitra4؛ M. R Islam5؛ K Dhama* 6
1Department of Pharmacy, State University of Bangladesh, 77 Satmasjid Road Dhanmondi, Dhaka-1205, Bangladesh
2Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka, Dhaka-1000, Bangladesh
3Department of Pharmacy, BGC Trust University, Chittagong-4381, Bangladesh
4Department Pharmacy, Faculty of Pharmacy, University of Dhaka, Dhaka-1000, Bangladesh
5Department of Pharmacy, University of Asia Pacific, 74/A, Green Road, Farmgate, Dhaka 1205, Bangladesh
6Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly-243122, Uttar Pradesh, India
چکیده
Low-income countries (LICs) and lower-middle-income countries (LMICs) are still deprived of the optimum doses of coronavirus disease 2019 (COVID-19) vaccines for their population, equal access and distribution, as well as mass immunization roadmaps to be implemented for achieving herd immunity and protection from the ongoing pandemic. In this short report, we are interacting with the world public health experts, as well as national and global leaders for warranting the mass vaccination drive to be more progressive against COVID-19 with equitable access of vaccines to LICs or LMICs to save the lives of the poorest country people and refugees. From several scientific databases, such as Google Scholar, PubMed, as well as national and international news websites, the data were collected data by utilizing appropriate keywords regarding the topic. Bangladesh might be exemplified in this brief communication as the representative of LMIC. As of October 14, 2021, 48% of the world's people have received at least one dose of the COVID-19 vaccine. In contrast, only 2.5% of people from LICs have come in under COVID-19 vaccination for at least a single shot. Both LICs and LMICs need far more vision and ambition, including political, administrative, and diplomatic progress along with enhancing the vaccination drive for their population to be immunized through simultaneous mass vaccination progress of other countries with implementing public health safety measures against the COVID-19 pandemic.
کلیدواژه‌ها
Bangladesh؛ COVID-19 outbreak؛ Lower-middle-income country (LMIC)؛ Successful mass vaccination
سایر فایل های مرتبط با مقاله
مراجع
  1. Bari MS, Hossain MJ, Akhter S, Emran TB. Delta variant and black fungal invasion: A bidirectional assault might worsen the massive second/third stream of COVID-19 outbreak in South-Asia. Ethics Med Public Health. 2021; 19: 100722.
  2. Hossain MJ, Kuddus MR, Rahman SMA. Knowledge, attitudes, and behavioral responses toward COVID-19 during early phase in Bangladesh: a questionnaire-based study. Asia Pac J Public Health. 2021;33(1):141-144.
  3. WHO Coronavirus (COVID-19) Dashboard. Accessed: October 15, 2021. Available from: https://covid19.who.int/table.
  4. García-Montero C, Fraile-Martínez O, Bravo C, Torres-Carranza D, Sanchez-Trujillo L, Gómez-Lahoz AM, et al. An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times. Vaccines. 2021; 9(5):433.
  5. Iqbal Yatoo M, Hamid Z, Parray OR, Wani AH, Ul Haq A, Saxena A, et al. COVID-19 - Recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines. Hum Vaccin Immunother. 2020; 16(12):2891-2904.
  6. Rawat K, Kumari P, Saha L. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. Eur J Pharmacol. 2021; 892.
  7. WHO. DRAFT landscape of COVID-19 candidate vaccines. Available from:https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
  8. Hossain MJ, Rahman SMA. Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress. Expert Rev Anti Infect Ther. 2021;19(8):1009-1027.
  9. Haider T, Gour V, Pandey V, Kanwar IL, Tiwari R, Vishwakarma M, et al. COVID-19 Infection: Targeting Possibilities for Treatment. Crit Rev Ther Drug Carrier Syst. 2021;38(3):75-115.
  10. Iqbal Yatoo M, Hamid Z, Rather I, Nazir QUA, Bhat RA, Ul Haq A, et al. Immunotherapies and immunomodulatory approaches in clinical trials - a mini review. Hum Vaccin Immunother. 2021;17(7):1897-1909.
  11. Rabaan AA, Al-Ahmed SH, Sah R, Tiwari R, Yatoo MI, Patel SK, et al. SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. Ann Clin Microbiol Antimicrob. 2020;19(1):40.
  12. Rabaan AA, Al-Ahmed SH, Muhammad J, Khan A, Sule AA, Tirupathi R, et al. Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm. Vaccines. 2021;9(5):436.
  13. Hossain MJ, Jannat T, Brishty SR, Roy U, Mitra S, Rafi MO, et al. Clinical Efficacy and Safety of Antiviral Drugs in the Extended Use against COVID-19: What We Know So Far. Biologics. 2021; 1(2):252-284.
  14. Blasi F, Gramegna A, Sotgiu G, Saderi L, Voza A, Aliberti S, Amati F. SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity. Respir Med. 2021;180: 106355.
  15. Dhama K, Sharun K, Tiwari R, Dhawan M, Emran TB, Rabaan AA, Alhumaid S. COVID-19 vaccine hesitancy - reasons and solutions to achieve a successful global vaccination campaign to tackle the ongoing pandemic. Hum Vaccin Immunother. 2021;17(10):3495-3499.
  16. Farooqi T, Malik JA, Mulla AH, Al Hagbani T, Almansour K, Ubaid MA, Alghamdi S, Anwar S. An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies. J Infect Public Health. 2021;14(10):1299-1312.
  17. Lai CC, Chen IT, Chao CM, Lee PI, Ko WC, Hsueh PR. COVID-19 vaccines: concerns beyond protective efficacy and safety. Expert Rev Vaccines. 2021;20(8):1013-1025.
  18. Raman R, Patel KJ, Ranjan K. COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. Biomolecules. 2021;11(7):993.
  19. Sharun K, Dhama K. COVID-19 Vaccine Diplomacy and Equitable Access to Vaccines Amid Ongoing Pandemic. Arch Med Res. 2021;52(7):761-3.
  20. Snehota M, Vlckova J, Cizkova K, Vachutka J, Kolarova H, Klaskova E, Kollarova H. Acceptance of a vaccine against COVID-19 - a systematic review of surveys conducted worldwide. Bratisl Lek Listy. 2021;122(8):538-547.
  21. Tareq AM, Emran TB, Dhama K, Dhawan M, Tallei TE. Impact of SARS-CoV-2 delta variant (B.1.617.2) in surging second wave of COVID-19 and efficacy of vaccines in tackling the ongoing pandemic. Hum Vaccin Immunother. 2021;2:1-2.
  22. Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, Teerawattananon Y, Jit M. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet. 2021;397(10278):1023-1034.
  23. Yan ZP, Yang M, Lai CL. COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials. Pharmaceuticals. 2021;14(5):406.
  24. Hossain MJ, Kuddus MR, Rashid MA, Sultan MZ. Understanding and Dealing the SARS-CoV-2 Infection: An Updated Concise Review. Bangladesh Pharm J. 2021;24(1): 61–75.
  1. Garg S, Singh MM, Deshmukh CP, Bhatnagar N, Borle AL, Kumar R. Critical interpretative synthesis of herd immunity for COVID-19 pandemic. J Family Med Prim Care. 2021;10(3):1117-1123.
  2. Redwan EM. COVID-19 pandemic and vaccination build herd immunity. Eur Rev Med Pharmacol Sci. 2021;25(2):577-579.
  3. Solís Arce JS, Warren SS, Meriggi NF, et al. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. Nat Med. 2021;27(8):1385-1394.
  4. Hossain MJ. Is Bangladesh moving toward herd Immunity? current COVID-19 perspective. Bangladesh J Infect Dis. 2020;7(2):63-6.
  5. Schaffer DeRoo S, Pudalov NJ, Fu LY. Planning for a COVID-19 Vaccination Program. J Am Med Assoc. 2020;323(24):2458-2459.
  6. Cihan P. Forecasting fully vaccinated people against COVID-19 and examining future vaccination rate for herd immunity in the US, Asia, Europe, Africa, South America, and the World. Appl Soft Comput. 2021;111:107708.
  7. Kadkhoda K. Herd Immunity to COVID-19. Am J Clin Pathol. 2021;155(4):471-472.
  8. Sharma N, Vyas S, Mohapatra A, Khanduri R, Roy P, Kumar R. Combating COVID-19 pandemic in India: Demystifying the concept of herd immunity. J Family Med Prim Care. 2021;10(4):1515-1519.
  9. Boehm E, Kronig I, Neher RA, Eckerle I, Vetter P, Kaiser L; Geneva Centre for Emerging Viral Diseases. Novel SARS-CoV-2 variants: the pandemics within the pandemic. Clin Microbiol Infect. 2021;27(8):1109-1117.
  10. Caldwell JM, Le X, McIntosh L, Meehan MT, Ogunlade S, Ragonnet R, O'Neill GK, Trauer JM, McBryde ES. Vaccines and variants: Modelling insights into emerging issues in COVID-19 epidemiology. Paediatr Respir Rev. 2021;39:32-39.
  11. Sharun K, Tiwari R, Dhama K, Emran TB, Rabaan AA, Al Mutair A. Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies. Hum Vaccin Immunother. 2021;17(10):3491-3494.
  12. Hassan AM. COVID-19 vaccination: How’s Bangladesh doing compared to the rest of the world? Daily Star.Accessed October15,2021. Available from: https://www.thedailystar.net/coronavirus-deadly-new-threat/news/covid-19-vaccination-hows-bangladesh-doing-


   compared-the-rest-the-world-2049289.

  1. Our World in Data. Coronavirus vaccinations. Accessed October 14, 2021. Available from: https://ourworldindata.org/covid-cases.
  2. Hossain MJ, Soma MA, Islam MR, Emran TB. Urgent call for actionable measures to fight the current co-epidemic of dengue burden during the SARS-CoV-2 delta variant era in South-Asia. Ethics Med Public Health. 2021;19:100726.
  3. Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta KD, et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med. 2021.
  4. Jamil K, Bhuiya A, Streatfield K, Chakrabarty N. The immunization programme in Bangladesh: impressive gains in coverage, but gaps remain. Health Policy Plan. 1999;14(1):49-58.
  5. World Health Organization. World polio day: Bangladesh continues efforts to sustain the polio-free status. Accessed October 15, 2021. Available from: https://www.who.int/bangladesh/news/detail/28-10-2019-world-polio-day-bangladesh-continues-efforts-to-sustain-the-polio-free-status.
  6. Hossain MJ. Impact of COVID-19 Pandemic among health care providers in Bangladesh: a systematic review. Bangladesh J Infect Dis. 2020;7(2): 8-15.
  7. Hossain MJ. Social Organizations and Mass Media in COVID-19 Battle: A Bidirectional Approach in Bangladesh. Asia Pac J Public Health. 2021;33(4):467-468.
  1. Tribune report. Bangladesh clears Johnson & Johnson’s single-dose Covid-19 vaccine for use. Accessed October 15, 2021. Available from: https://www.dhakatribune.com/health/coronavirus/2021/06/15/johnson-johnson-s-covid-19-vaccine-approved-for-emergency-use.
  2. Machingaidze, S., Wiysonge, C.S. Understanding COVID-19 vaccine hesitancy. Nat Med. 2021; 27:1338–1339.
  3. The logistics of mass vaccination in Bangladesh and beyond. UK Research and Innovation. Accessed October 15, 2021. Available from: https://www.birmingham.ac.uk/news/latest/2020/09/blueprint-to-vaccinate-in-Bangladesh.aspx.
  4. Kondilis E, Papamichail D, McCann S, et al. The impact of the COVID-19 pandemic on refugees and asylum seekers in Greece: A retrospective analysis of national surveillance data from 2020. EClinicalMedicine. 2021; 37: 100958.
  5. Molla MMA, Disha JA, Yeasmin M, Ghosh AK, Nafisa T. Decreasing transmission and initiation of countrywide vaccination: Key challenges for future management of COVID-19 pandemic in Bangladesh. Int J Health Plann Manage. 2021.
آمار
تعداد مشاهده مقاله: 15,346
تعداد دریافت فایل اصل مقاله: 56,041


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب